RESUMEN
Uropathogenic Escherichia coli (UPEC) accounts for the majority of complicated and uncomplicated urinary tract infections. The use of phytomolecules in the treatment of UTI is fast gaining attention. The current report identifies a multidrug-resistant strain (QSLUPEC7), which is a strong biofilm producer, among the considered clinical isolates. The antimicrobial and antibiofilm activity was evaluated for the phytomolecule, Type A procyanidin (TAP) from Cinnamomum zeylanicum against QSLUPEC7. TAP treatment did not affect the growth of the MDR strain but affected the biofilm formation (~70% inhibition). The confocal microscopic examination reveals the biofilm inhibition and the live cells in the biofilm corroborates the antimicrobial results. Further, the synergy studies of TAP and nitrofurantoin (NIT) were carried out at different pH. TAP acts synergistically with nitrofurantoin at different pH considered. A closer look in the results reveals that at pH 5.8, maximum growth inhibition is recorded. The gene expression analysis shows that TAP alone and in combination with NIT downregulates the major fimbriae adhesins of UPEC. The results conclude that the TAP has an antibiofilm activity against the multidrug-resistant strain of UPEC, without affecting the growth. Also, TAP reciprocally cooperates with nitrofurantoin at different pH by downregulating the adhesins of UPEC.
Asunto(s)
Infecciones por Escherichia coli , Preparaciones Farmacéuticas , Infecciones Urinarias , Escherichia coli Uropatógena , Biflavonoides , Biopelículas , Catequina , Humanos , Concentración de Iones de Hidrógeno , Nitrofurantoína/farmacología , Proantocianidinas , Infecciones Urinarias/tratamiento farmacológicoRESUMEN
BACKGROUND AND AIMS: Chronic hepatitis C virus (HCV) infection is a major cause of liver disease worldwide. Although direct-acting antivirals can cure the large majority of treated patients, important limitations remain, including treatment failure and high costs precluding access to therapy in resource-limited settings. We report herein the anti-HCV effects of IND02, a procyanidin type A molecule, isolated and characterized from cinnamon. METHODS AND RESULTS: Using cellculture-derived HCV (HCVcc), HCV pseudoparticles (HCVpp), and subgenomic replicons, we demonstrated that IND02 markedly and dose-dependently inhibited HCV cell entry. Kinetic assays demonstrated that IND02 inhibits HCV entry most likely at a postbinding step. Experiments performed using primary human hepatocytes confirmed inhibition of HCV entry by IND02, demonstrating the functional impact in the most physiological cell-based system for studying HCV-host interactions. CONCLUSIONS: The natural compound IND02 exhibits potent HCV cell entry inhibition and provides a novel perspective for development of a low-cost antiviral for treatment of HCV infection.
Asunto(s)
Antivirales/farmacología , Biflavonoides/farmacología , Catequina/farmacología , Cinnamomum zeylanicum , Hepacivirus/efectos de los fármacos , Hepatitis C Crónica/tratamiento farmacológico , Proantocianidinas/farmacología , Antivirales/uso terapéutico , Biflavonoides/uso terapéutico , Catequina/uso terapéutico , Relación Dosis-Respuesta a Droga , Hepacivirus/fisiología , Humanos , Proantocianidinas/uso terapéuticoRESUMEN
Objective: To assess the safety and efficacy of herbal formulation rich in standardized fenugreek seed extract (IND-2) add-on therapy in type 2 diabetes mellitus (T2DM) patients who were on insulin treatment in prospective, single arm, open-label, uncontrolled, multicentre trial. Methods: T2DM patients (n=30) with aged 18-80 years who were stabilized on insulin treatment with fasting blood sugar (FBS) level between 100-140 mg/dL received IND-2 capsules (700 mg, thrice a day) for 16 weeks. The primary endpoints were an assessment of FBS at week 2, 4, 6, 8, 12 and 16. Secondary end-points include post-prandial blood sugar level, glycosylated Hb (HbA1c), reduction in the dose of insulin and number of hypoglycemic attacks, and improvement in lipid profile at various weeks. Safety and adverse events (AEs) were also assessed during the study. Results: Study was completed in twenty T2DM patients, and there was no significant reduction in FBS and post-prandial blood sugar level after add-on therapy of IND-2. However, add-on therapy of IND-2 significantly reduced (P<0.01) the HbA1c values, requirements of insulin and hypoglycemic events as compared with baseline. Total cholesterol, high-density lipoproteins-cholesterol, and low-density lipoprotein-cholesterol levels were significantly increased (P<0.01) after IND-2 add-on therapy. Body weight and safety outcomes did not differ significantly in IND-2 add-on therapy group at week 16. Additionally, add-on therapy of IND-2 did not produce any serious adverse events. Conclusions: The results of present investigation suggest that add-on therapy of IND-2 with insulin in T2DM patients improves glycaemic control through a decrease in levels of HbA1c and number of insulin doses needed per day without an increase in body weight and risk of hypoglycemia. Thus, IND-2 may provide a safe and well-tolerated add-on therapy option for the management of T2DM.
RESUMEN
Background: Cardiovascular disease is a leading cause of death in India. In orderto reduce the burden of the disease, it is important to know the level of modifiablerisk factors in the population. The aim of this study was to estimate the prevalenceof hypercholesterolaemia and associated factors among the population aged over30 years in a rural area in north Kerala, India.Methods: A cross-sectional study was carried out to find the prevalence ofhypercholesterolaemia among 533 residents of Kulappuram village. The fastingblood glucose level, total serum cholesterol level, blood pressure and body massindex of the residents were also assessed. The significance of association ofhypercholesterolaemia with age, sex, body mass index and blood pressure wastested using the chi-squared test. Logistic regression was carried out to estimatethe adjusted odds ratios (OR).Results: The prevalence of hypercholesterolaemia was 63.8%. It was moreprevalent in women (adjusted OR: 1.56; 95% confidence interval [CI]: 1.07–2.27),in those with body mass index in the range 23.0–24.9 kg/m2 (adjusted OR: 1.78;95% CI: 1.04–3.02) and in those with blood pressure ≥140/90 mmHg (adjustedOR: 1.62; 95% CI: 1.1–2.38).Conclusion: The prevalence of hypercholesterolaemia is high in the studypopulation